New developments in A1 and A2 adenosine receptor antagonists

Pure and Applied Chemistry

Volumn 73, Issue 9, 2001, Pages 1411-1420

  Kiec Kononowicz K ^a   Drabczynska A ^a   Pekala E ^a   Michalak, B ^a   Muller C E ^a   Schumacher, B ^a   Karolak Wojciechowska, J ^a   Duddeck, H ^a   Rockitt, S ^a   Wartchow, R ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N (5 HYDROXYNORBORNAN 2 YL) 8 (N ISOPROPYL N METHYLAMINO) 9 METHYLADENINE; 6 OXO 3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1(6H) PYRIDAZINEBUTYRIC ACID; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 (3,4 DIMETHOXYSTYRYL) 1,3 DIETHYL 7 METHYLXANTHINE; 8 (5,6 EPOXY 2 NORBORNYL) 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; MRS 1706; MRS 1754; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; CONFERENCE PAPER; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0035742825     PISSN: 00334545     EISSN: None     Source Type: Journal    
DOI: 10.1351/pac200173091411     Document Type: Conference Paper

References (62)